PFF Clinical Trial Finder

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

Study Purpose

A phase 2b, open label study to assess the safety and efficacy of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis and sarcoidosis on long term oxygen therapy followed by a long term extension study

Recruitment Criteria

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Accepts Healthy Volunteers

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Study Type
Eligible Ages 18 Years - 85 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Signed informed consent 2. A primary diagnosis of sarcoidosis as defined by the ATS/ERS/WASOG statement or pulmonary fibrosis associated with one of the following conditions: 2.1 Major IIPs (idiopathic interstitial pneumonias) diagnosed or suspected as one of the following:
  • - Idiopathic pulmonary fibrosis - Idiopathic nonspecific interstitial pneumonia - Respiratory bronchiolitis-interstitial lung disease - Desquamative interstitial pneumonia - Cryptogenic organizing pneumonia - Acute interstitial pneumonia - Rare IIPs diagnosis by one of the following: - Idiopathic lymphoid interstitial pneumonia - Idiopathic pleuroparenchymal fibroelastosis - Unclassifiable idiopathic interstitial pneumonias 2.2 Chronic hypersensitivity pneumonitis 2.3 Occupational lung disease 2.4 Connective tissue disease with evidence of significant pulmonary fibrosis 3.
Intermediate or high probability of PH by echocardiogram as assessed by local Radiologist/Investigator, or PH as determined by a right heart catheterization (RHC) within 5 years prior to Baseline with the following parameters: 1. Pulmonary vascular resistance (PVR) ˃3 Wood Units (WU) (320 2. A left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg 3. A mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg 4. 6MWD ≥ 100 meters and ≤ 450 meters 5. WHO Functional Class II-IV 6. Forced Vital Capacity ≥ 40% predicted within last 6 weeks prior to screening 7. Females of childbearing potential must have a negative pre-treatment pregnancy test (urine). 8. Age between 18 and 85 years (inclusive) 9. Clinically stable for at least 4 weeks prior to Baseline in the opinion of the Investigator 10. If on therapy for their parenchymal lung disease and/or sarcoidosis, then the subject should be on a stable well-tolerated dose of the medication(s) for at least 4 weeks prior to enrollment.

Exclusion Criteria:

1. Use of any type of PAH specific therapies 2. Episodes of disease worsening within 3 months prior to Baseline 3. Pregnant or breastfeeding females at Screening 4. Administered L-arginine within 1 month prior to Screening 5. Any subject who has been enrolled in any previous clinical study with inhaled NO administered through pulsed delivery 6. On more than 6 L/min of oxygen at rest by nasal cannula for less than 4 weeks 7. Evidence of any connective tissue disease with FVC > 60% in the last 6 months prior to screening unless there is evidence of moderate to severe fibrosis on CT scan in the opinion of the local radiologist/Investigator 8. Evidence of clinically significant combined pulmonary fibrosis with emphysema (CPFE) if > 15% of lung fields by CT scan show evidence of emphysema in the opinion of the local radiologist/Investigator 9. For subjects with sarcoidosis, clinically significant evidence of pulmonary fibrosis on CT scan in the opinion of the local radiologist/Investigator and FVC ≥80% predicted 10. For subjects continuing on open label therapy, the concurrent use of the INOpulse device with a CPAP/BiPAP, or any other positive pressure device 11. Significant heart failure in the opinion of the Investigator 1. LVEF<40% or 2. PCWP on last RHC>15 mmHg (unless concurrent LVEDP <15 mmHg) or 3. Significant diastolic dysfunction on echocardiogram

Trial Details

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

Trial ID:

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Lead Sponsor

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator
Hunter Gillies, MD
Principal Investigator Affiliation Bellerophon Pulse Technologies

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Agency Class
Overall Status Not yet recruiting

The disease, disorder, syndrome, illness, or injury that is being studied.

Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Additional Details

A phase 2b, open label study to assess the hemodynamic effects of increasing doses of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary hypertension associated with pulmonary fibrosis or sarcoidosis on long term oxygen therapy followed by an open label extension study

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Valerie Parker


For additional contact information, you can also visit the trial on

Terms of Service

The PFF does not promote or represent that any investigational new drugs mentioned are safe or effective. The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. For a full description of terms please refer to our Terms, Conditions & Privacy.

Back to Top
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >